Unten finden Sie die vollständige Liste unserer Pressemitteilungen (Seite 12 von 28):
Conduit secures patent for a novel AZD5904 form with better solubility, extending IP and enabling development in infertility and inflammation-linked diseases.
Zepbound led to 47% more weight loss than Wegovy in a head-to-head Phase 3b obesity trial, with greater waist reduction and a favourable safety profile.
Addex and Indivior advance their GABAB PAM program to clinical stage after clearing IND-enabling studies, targeting treatment for substance use disorders.
FDA and CDC pause IXCHIQ® use in adults 65+ during safety review. Valneva backs global investigations and continues monitoring vaccine safety | Pharma Now.
Trixeo Aerosphere UK approval marks the first inhaled COPD drug with a low-GWP propellant, cutting carbon footprint by 99.9%.
REAL8 Phase 3 study shows once-weekly Sogroya® matches daily treatment for SGA, Noonan syndrome & ISS, offering a well-tolerated, effective option.
Amylyx shares 48-week Phase 2 HELIOS trial data for AMX0035 in Wolfram syndrome, showing sustained efficacy and favorable safety profile | Pharma Now.
Syndax Pharmaceuticals appoints Dr. Nicholas Botwood as Head of R&D and CMO, bringing 25+ years of oncology leadership experience from BMS and AstraZeneca.
Ascendis Pharma reveal 214-week Phase 2 data showing lasting benefits of TransCon PTH in adults with hypoparathyroidism and a strong safety profile | Pharma Now
Curium secures Swiss approval for PYLCLARI® to detect PSMA-positive lesions in prostate cancer patients, expanding its EU rollout to 12 countries.
Federal Circuit sends CRISPR patent case back to PTAB; Editas says ruling won't affect its CRISPR/Cas12a patents or licensing strategy.
Moleculin gets EMA approval to expand its Phase 3 MIRACLE trial for Annamycin in relapsed or refractory AML with sites across the US, EU, and Middle East.
Revive and DRDC advance Bucillamine research for nerve agent exposure; human trials may begin in late 2025 pending positive preclinical results.
ElevateBio names Ger Brophy, Ph.D., as Interim CEO and Board member, succeeding David Hallal. Brophy focuses on expanding genetic medicine capabilities.
Biodexa receives Orphan Drug Designation from the EC for eRapa in treating familial adenomatous polyposis (FAP), advancing toward Phase 3 study.
Dr. Launa Aspeslet appointed Chief Translational Officer at API to lead life sciences commercialization and support innovation across Canada.
ACELYRIN stockholders approve merger with Alumis to advance therapies for immune-mediated diseases. Completion expected in Q2 2025.
Capricor names Dr. Michael Binks as CMO to lead deramiocel's development for Duchenne muscular dystrophy and expand future pipeline.
Renovaro and Amsterdam UMC collaborate on blood platelet RNA diagnostics, aiming to revolutionize cancer detection using AI and ML technologies.
Connect Biopharma initiates Phase 2 Seabreeze study to test rademikibart for acute asthma exacerbations, aiming to improve lung function in asthma patients.
HCW9206 shows superior CAR-T cell performance; HCW Biologics prepares for commercial sales following FDA filing and new study data.
Oragenics gains HREC approval to start Phase II trial of ONP-002 for concussion treatment in Australia, advancing a new therapy for brain injury.
Erasca clears FDA IND for ERAS-0015, secures 3+ years of cash runway, and targets RAS-mutant cancers with promising therapies in early clinical stages.
BMB-101 eliminated drop seizures and boosted survival in DBA/2 mice, showing promise for drug-resistant epilepsy and SUDEP prevention.
CytoDyn reveals that leronlimab increases PD-L1 in tumors, potentially turning "cold" tumors "hot" and improving response to immunotherapy.
Join Asia Labex 2025 at BIEC, Bengaluru, from June 11-13, with Pharma Now as media partner, featuring 300+ exhibitors, 7,000+ products, seminars, and networking.
Explore the NutrifyToday C-Suite SumFlex 2025 in Mumbai, where global leaders in nutraceuticals, pharma, and policy unite to drive India's growth.
Pharma Now partners with the 4th GPCR-Targeted Drug Discovery Summit 2025 in Boston, offering exclusive coverage on next-gen GPCR therapeutics, featuring insights from industry leaders.
Tonix Pharmaceuticals appoints Joseph Hand as General Counsel & Executive Vice President of Operations, strengthening leadership ahead of TNX-102 SL launch.
Surrozen receives U.S. Patent for SWAP™ technology, targeting Wnt pathway receptors to enhance tissue repair and regeneration.
Therini Bio raises $39M in Series A to fund Phase 1b trials for THN391 targeting Alzheimer's and Diabetic Macular Edema.
Connect Biopharma launches Phase 2 Seabreeze STAT study to test rademikibart for treating acute COPD exacerbations with type 2 inflammation.
Hilary Kramer joins GT Biopharma's Board, bringing financial expertise to support strategic growth and advance its immuno-oncology pipeline.
Pharma Now is the official media partner for the 5th India Biopharma Leaders Conclave, June 5-6, 2025, in Hyderabad, focusing on biosimilars, biologics, and industry advancements.
Merck's KEYTRUDA achieved significant benefits in the Phase 3 KEYNOTE-B96 trial for platinum-resistant ovarian cancer, improving progression-free survival.
Autonomix secures U.S. patent for catheter-based nerve mapping and ablation system; trials for pancreatic cancer pain begin in 2025.
Amneal’s Brekiya autoinjector gains FDA approval as the first self-administered DHE treatment for migraines and cluster headaches.
Hikma sets 2030 revenue target of $5B, introduces new guidance and rebrands Generics as Hikma Rx at Ohio facility event.
Voyager's VCAP-102 capsid crosses the blood-brain barrier via ALPL receptor, enabling efficient CNS gene delivery in primates.
Pharma Now is the official media partner of the 2nd Annual Structure-Based Drug Design, June 3-5, 2025, in Boston.
Pharma Now is the official media partner of the 3rd Global Pharma Tech Summit 2025, Zurich, June 23–24, exploring pharma innovation.
BlueSphere Bio appoints Dr. Alan Korman as CSO to lead TCR-T cell therapy innovation, bringing 30+ years of expertise in immunology and drug discovery.
Novo Nordisk CEO Lars Jørgensen will step down amid market pressure; ex-CEO Lars Sørensen joins board meetings as observer.
BioMarin will acquire Inozyme Pharma for $270M in cash, adding late-stage therapy INZ-701 for ENPP1 Deficiency to its rare disease portfolio.
Pharma Now partners with the European Pharma Outsourcing Summit 2025 in Düsseldorf, covering insights on outsourcing, manufacturing, and supply chain.
Pharma Now has launched its official mobile app, offering real-time news, expert insights, and global pharma event updates—available on Google Play Store and App Store.
AstraZeneca’s Airsupra (albuterol/budesonide) reduced severe asthma exacerbations by 47% in the Phase IIIb BATURA trial.
Regeneron secures 23andMe’s Personal Genome Service®, Biobank, and health research assets for $256M, expanding its genetic research capabilities.
Daiichi Sankyo and Merck begin Phase 3 trial of I-DXd in advanced ESCC patients post-chemotherapy and immunotherapy.
Chugai Pharma Taiwan earns TFDA approval for PiaSky® to treat PNH in patients 13+ years old and 40+ kg, based on Phase III COMMODORE studies.
Rejuvenate Biomed starts Phase 2 trial of RJx-01 in older COPD patients with muscle weakness, backed by Wellcome Leap.
Alvotech appoints DNB Carnegie as liquidity provider for its SDRs on Nasdaq Stockholm to boost trading stability.
Acoramidis raises serum TTR early, lowering death risk in ATTR-CM patients.
Don Haut joins Arbor Biotechnologies to lead business strategy and partnerships for gene editing therapies.
Steven Johnson joins Zealand Pharma to lead development and regulatory strategies in obesity treatment innovation.
Rick Austin joins VERAXA Biotech as CSO to advance cancer therapy pipeline and BiTAC platform.
Oruka begins Phase 1 trial of ORKA-002, a long-acting IL-17A/F antibody for psoriasis; first participants dosed in safety and PK study.
GENFIT earns €26.5M milestone as Italy approves pricing and reimbursement for Ipsen’s Iqirvo® in PBC treatment.
Columvi + GemOx improves survival in relapsed DLBCL; FDA advisory panel requests more U.S. data before approval decision.
Marker’s MT-601 MAR-T cells expand better and show stronger clinical activity with lymphodepletion, as Phase 1 lymphoma trial enrollment accelerates.
Aligos Therapeutics names Laura Kavanaugh VP, Head of Legal, bringing 25+ years of biotech legal experience to support its clinical-stage programs.
AstraZeneca completes acquisition of EsoBiotec for up to $1B, boosting in vivo cell therapy capabilities via ENaBL platform.
Astoriom has expanded its Tramore, Ireland site to boost cryogenic and ICH-compliant stability storage, strengthening its global biorepository network.
Chugai’s Phase III TALENTACE trial shows TACE PFS benefit for unresectable HCC with Tecentriq, Avastin & TACE; OS data immature at prespecified first interim analysis.
Tonix starts Phase 2 OASIS trial of TNX-102 SL to reduce acute stress symptoms in trauma patients; funded by $3M DoD grant and UNC Trauma Institute.
Silo Pharma teams with Resyca for a study of its microchip nasal spray system for SPC-15, a novel PTSD prophylactic; IND-enabling studies ongoing.
Sandoz debuts Europe’s first ustekinumab biosimilar autoinjector, Pyzchiva®, boosting comfort and adherence in chronic disease treatment.
Trethera welcomes Dr. Benjamin Greenberg to its SAB to guide TRE-515's clinical development for optic neuritis and ADEM, rare autoimmune CNS diseases.
Dr. Gayathri Ramaswamy presented RIPK2 PROTAC degraders at DDC 2025, spotlighting Aurigene’s approach to targeted drug discovery and synthesis.
SynVivo appoints Dr. Richard Eglen to its Board, boosting scientific leadership to advance organ-on-chip tech for better drug discovery and development.
Sanofi to acquire Vigil Neuroscience for $470M, gaining rights to VG-3927, a potential TREM2-based treatment for Alzheimer’s. Deal to close in Q3 2025.
OSE teams with Inside Therapeutics & MiNT Lab on HexARN project to develop mRNA therapies, supported by €1.3M France 2030 grant via Bpifrance.
Medicus Pharma to begin Phase 2 UAE trial of non-invasive basal cell carcinoma treatment at four major hospitals.
Sernova forms Clinical Advisory Board led by Dr. Robert Gabbay to support the Cell Pouch platform for type 1 diabetes.
Astellas and Pfizer report 5- and 8-year data: XTANDI reduces death risk in metastatic prostate cancer by 30%.
PacBio and Haorui Gene partner to expand HiFi sequencing in China for clinical genomics and blood typing.
FDA approves Susvimo, Roche’s implant for diabetic retinopathy, offering vision protection with one refill every nine months.
Dianthus Therapeutics adds Simon Read, Ph.D., industry veteran, to its board as it advances antibody complement therapies for autoimmune diseases.
In an exclusive Pharma Now interview, Dr. Tathagata Dutta shares insights on pharma innovation, DNA research, leadership, and India's future in biologics.
Bachem, a Swiss peptide manufacturing company rolls out major investments across its site networks in US, UK and Switzerland
New biotech ABLi Therapeutics debuts to develop c-Abl kinase inhibitors, led by Risvodetinib for Parkinson’s and related disorders.
Vivoryon gains U.S. composition of matter patent for varoglutamstat, reinforcing its IP portfolio and advancing kidney disease treatment innovation.
CHMP recommends AstraZeneca’s Imfinzi for MIBC in the EU, citing NIAGARA trial results showing 32% risk reduction in disease progression.
Bio-Thera and Hikma receive FDA approval for STARJEMZA®, a Stelara® biosimilar, for plaque psoriasis and more.
C4X earns €8M from Sanofi for progress on oral IL-17A inhibitor, aiming to treat psoriasis and other inflammatory diseases with an oral therapy.
Rocket’s Phase 2 trial for Danon disease gene therapy is on FDA hold following a patient SAE and death. The company investigates and adjusts cash priorities.
Ocugen receives Rare Pediatric Disease Designation for OCU410ST, targeting Stargardt and other ABCA4-related eye diseases. Phase 2/3 trial to launch soon.
Biogen and City Therapeutics launched an RNAi drug collaboration targeting CNS diseases; the deal is worth up to $1B in milestones plus royalties.
ImmunityBio signs MOU with Saudi entities to deploy its FDA-approved Cancer BioShield in the Middle East, advancing immune-restorative therapies.
Novartis begins tender offer to acquire Regulus for $7/share plus CVR, expiring June 24, 2025; board recommends shareholder acceptance.
Altamira partners with undisclosed biotech to test its CycloPhore™ platform for delivering circular RNA; potential licensing may follow.
Acadia names Allyson McMillan-Youngblood SVP, Rare Disease Franchise, to drive DAYBUE® success and lead future product launch strategies.
VIVUS expands access to QSYMIA for weight loss, now offered at Costco Pharmacies with affordable pricing for Costco members.
Teva’s TEV-53408 earns FDA Fast Track for celiac disease, aiming to ease symptoms in patients on a gluten-free diet through IL-15 inhibition.
Coherus and STORM start Phase 1b/2 trials of STC-15 plus LOQTORZI for NSCLC, melanoma, and other cancers.
BC Platforms names Keith Collier as Chief Product Officer and Michele Lichtenfield as EVP & Head of Global Marketing to expand its Real-World Data impact and innovation.
Quantum BioPharma receives Australian ethics approval for a 60-patient trial testing FSD202 in chronic pain from MCAS, targeting major inflammatory disorders.
Telesis Bio licenses its high-throughput Gibson SOLA platform to Regeneron, enabling rapid, in-house DNA/mRNA synthesis to speed biologics R&D.
Charles River and CHDI Foundation extend their Huntington’s drug discovery collaboration, enhancing global R&D efforts with expanded AI and preclinical capabilities.
Alvotech and Advanz Pharma expand their biosimilar partnership with 3 new candidates, adding $180M in milestones and access to a $13.8B European market.
SCYNEXIS restarts Phase 3 MARIO trial for oral ibrexafungerp as step-down therapy for invasive candidiasis after FDA lifts clinical hold.
Eton Pharma's KHINDIVI™ gets FDA nod as first oral liquid hydrocortisone for kids 5+ with adrenal insufficiency.
FDA grants RMAT status to Candel’s CAN-2409 for localized prostate cancer after positive Phase 3 results showing improved disease-free survival.
ORIC-944 plus AR inhibitors shows early efficacy and safety in mCRPC Phase 1b trial, with strong PSA responses and mild to moderate side effects.
Taysha aligns with FDA on TSHA-102 pivotal trial design for Rett syndrome, backed by positive REVEAL data and Rett syndrome natural history insights.
Unbuzzd Wellness appoints MNP LLP for PCAOB audit as part of IPO prep, replacing Stern & Lovrics and advancing capital market plans.
Regeneron and Sanofi’s COPD drug itepekimab reduces exacerbations in the AERIFY-1 Phase 3 trial but misses primary endpoint in AERIFY-2.
BLA for patritumab deruxtecan in EGFR+ NSCLC withdrawn as HERTHENA-Lung02 trial misses OS endpoint; full data to be shared at ASCO 2025.
Auron Therapeutics doses first patient in Phase 1 trial of AUTX-703, a novel KAT2A/B degrader, for advanced AML and MDS treatment.
CC-42344 from Cocrystal Pharma shows strong antiviral effects against H5N1 avian flu, outperforming Tamiflu and advancing influenza treatment options.
Dr. Karen Chagin appointed Chief Medical Officer at Context Therapeutics, bringing 10+ years’ experience in T cell therapies for solid tumors.
CPHI Americas 2025 hosted 3,900+ attendees and 370+ exhibitors in Philadelphia, spotlighting pharma innovation, U.S. and LATAM markets, and global networking.
Pfizer's BRAFTOVI + cetuximab + mFOLFOX6 halved the risk of death in mutant metastatic colorectal cancer; OS improved to 30.3 months in the BREAKWATER Phase 3 trial.
AbbVie partners with the Chicago Cubs on the "Striking Out Cancer" campaign, donating $233 per strikeout to fight cancer.
Fate Therapeutics adds Neurocrine CFO Matthew Abernethy to its board; Timothy Coughlin steps down concurrently.
Nxera achieves a development milestone in its collaboration with Eli Lilly on diabetes, triggering a payment and progress toward $694M in milestones.
Novartis reports Kisqali reduces recurrence risk in early breast cancer, with greater benefit for younger, pre-menopausal patients.
VERIFY Phase 3 trial shows rusfertide significantly improves hematocrit control in polycythemia vera patients with good safety also met all endpoints.
Ziftomenib gets FDA Priority Review for treating relapsed/refractory NPM1-mutant AML. PDUFA date set for Nov 30, 2025.
In an exclusive Pharma Now interview, Dr. Rajput shares insights on pharma leadership, mentorship, and building solid professionals for the future.
Sandoz introduces WYOST® and Jubbonti®, the first interchangeable denosumab biosimilars in the U.S., expanding affordable access to osteoporosis and cancer care.
Novartis' Pluvicto shows significant rPFS benefit in PSMA+ mHSPC patients in Phase III trial, reinforcing its potential in earlier prostate cancer treatment.
Sutro Biopharma names Greg Chow as CFO. With 25+ years in finance and biotech, he’ll drive financial strategy and support ADC pipeline growth.
Dr. William Andrews named Chief Medical Officer at Catalyst Pharma, bringing 20+ years of biopharma and rare disease expertise.
Research backs Artelo’s FABP inhibitors as potential treatments for anxiety and depression with fewer side effects.
Elite Clinical Network names Christopher Brennan as CEO to drive growth and expand its clinical research site network and capabilities.
Dyadic names Joe Hazelton President to drive growth in ancillary proteins for life sciences, nutrition, and industry, aligning leadership with new focus.
Sernova names CEO Jonathan Rigby as interim Chair, continues financing talks, and announces CBO Dr. Modestus Obochi’s exit.
Roche’s Tecentriq-lurbinectedin combo cut disease progression risk by 46% in extensive-stage small cell lung cancer. The combo boosts survival in the ES-SCLC.
Neurocrine doses first patient in Phase 3 schizophrenia trial of NBI-‘568, triggering a $15M payment to Nxera, recorded as Q2 2025 revenue.
Renovaro gains U.S. patent to enhance its AI-driven platform for drug discovery and diagnostics, strengthening its precision medicine capabilities.
FABA launches India's first biotechnology finishing school, training graduates in lab skills, cell culture, and industry-ready soft skills in 27 days.
Chemomab gains new patents for nebokitug in China and Russia, boosting IP protection and advancing PSC treatment efforts globally.
Entrada appoints Dr. Maha Radhakrishnan to its Board, boosting leadership with deep drug development and biopharma expertise.
Rose Hill Life Sciences secures exclusive rights to Johns Hopkins' psilocybin-based therapies targeting motor function restoration in stroke and CNS injury patients.
Cognition Therapeutics initiates an expanded access program for zervimesine (CT1812) in DLB, funded by a philanthropic donation, across multiple U.S. sites.
Takeda gains EU approval for ADCETRIS® with ECADD in frontline Hodgkin lymphoma, based on the HD21 trial showing safer outcomes vs. standard care.
Amylyx earns FDA Fast Track for AMX0114 in ALS. Phase 1 trial underway to assess calpain-2-targeting ASOs’ safety, biomarkers, and neuroprotective effects.
Roche’s Evrysdi now approved in EU as a room-temperature stable 5mg tablet, offering convenience for SMA patients 2+ years old weighing at least 20kg.
Accumulus Synergy and Veeva Systems team up to boost global regulatory connectivity for life sciences firms via cloud interoperability.
Conduit and Manoira launch JV to test AZD1656 in animal osteoarthritis, boosting R&D for both human and veterinary markets.
Shuttle Pharma appoints veteran executive George Scorsis as Chairman to lead strategic oncology advancements.
Oncovita’s MVdeltaC receives FDA Orphan Drug Designation for pleural mesothelioma treatment.
Moleculin’s Phase 1B/2 trial shows promising Annamycin results in soft tissue sarcoma lung metastases.
HCW Biologics completes key deliverable, secures $7M upfront, and finalizes license agreement with WY Biotech for novel immunotherapy HCW11-006.
Frédéric Robert joins EUROAPI as Chief Commercial Officer to lead API Solutions and CDMO operations, driving growth and global strategy.
Tempest Therapeutics secures EMA orphan drug designation for amezalpat in hepatocellular carcinoma (HCC), following strong Phase 2 survival data.
Valneva presents positive six-month safety and immune response data for IXCHIQ® chikungunya vaccine in children.
Autonomix receives Uzbekistan approval to start next-phase PoC 2 Cancer Pain clinical trial for nerve ablation in cancer pain management.
Hikma introduces Triamcinolone Acetonide injectable (40mg/mL) in the US, targeting inflammation and autoimmune disorders.
Alvotech and Dr. Reddy’s partner to co-develop, manufacture, and commercialize a biosimilar to Keytruda®, a $29.5B blockbuster cancer drug.
SELLAS Life Sciences adds Drs. Amrein and Kentsis to its Scientific Advisory Board to strengthen cancer therapy development and clinical strategy.
Kailera strengthens its Board with Adam Koppel and Christopher Hite to boost leadership in advancing next-gen obesity therapies.
FDA grants Orphan Drug Designation to Avadel’s LUMRYZ™ for treating idiopathic hypersomnia with once-nightly extended-release sodium oxybate.
VeonGen (formerly ViGeneron) advances VG801 gene therapy for Stargardt disease with FDA Rare Pediatric Disease Designation and ongoing clinical progress.
Vertex shares new data showing ALYFTREK’s superior clinical and quality of life outcomes for CF patients, with benefits linked to sweat chloride reduction.
MIT and Recursion launch Boltz-2, an open-source biomolecular AI model with near-FEP accuracy at 1,000x speed for scalable drug discovery.
Join the London Biotechnology Show on June 18–19, 2025, at ExCeL London. Explore cutting-edge science, transformative innovation, and forward-thinking leadership in biotech.
Apellis and Sobi report 68% sustained proteinuria reduction with EMPAVELI in C3G and IC-MPGN; safety remains consistent at 1 year.
Biomerica names Eric B. Chin to Board of Directors and Chair of Audit Committee, succeeding Cathy Coste. Mr. Chin is the CFO at Akido.
Shawn Rose appointed Nkarta’s CMO & R&D Head as company pivots to autoimmune therapies; succeeds Dr. Shook, who steps down to pursue oncology roles.
On Pharma Now’s YouTube podcast, ex-Wockhardt President Pradnya Deshmukh reveals key lessons in pharma leadership, regulatory excellence, and work-life balance—essential listening for future industry leaders.
Pharma Now proudly participated in the 5th Indian Biopharma Leaders Conclave 2025, connecting with top industry leaders.
Biotech veteran Dr. Michael Kauffman joins FibroGen’s board to support pipeline growth, oncology focus, and strategic development.
Dr. Srishti Gupta to become Idorsia's CEO from July 1, 2025, bringing 20+ years of experience to drive long-term success and portfolio growth.
Dr. Jayne Morgan joins Micron Biomedical to support education and access to needle-free, dissolvable drug and vaccine delivery solutions.
George Medicines' WIDAPLIK, a triple-combo pill, gets FDA nod to help adults control high blood pressure with once-daily, single-pill therapy.
Lyell appoints new board and executive leaders to drive LYL314 development, enhance governance, and support future commercial growth in CAR T-cell therapy.
Merck’s enlicitide met all endpoints in two Phase 3 trials, reducing LDL-C in statin-treated adults without major safety concerns.
Merck’s ENFLONSIA wins FDA approval for preventing RSV in infants, showing strong efficacy in lowering infection rates and hospitalizations over five months.
CervoMed hires Dr. Marco Verwijs as EVP, Technical Ops to lead CMC and support Phase 3 and commercial prep of neflamapimod for dementia with Lewy Bodies.
Dr. Michael Vasconcelles joins Day One as Head of R&D to lead research, development, and medical affairs, supporting OJEMDA and pipeline expansion.
FDA clears IND for Monte Rosa’s MRT-8102, a NEK7-targeting molecular glue degrader for inflammatory diseases; Phase 1 trial to start soon.
Jazz’s Zepzelca-Tecentriq combo earns U.S. FDA Priority Review for first-line maintenance in extensive-stage small cell lung cancer; PDUFA set for Oct 7, 2025.
Xilio Therapeutics names Dr. Tunde Bello to its board, bringing 25+ years of oncology and clinical pharmacology expertise from BMS and Pfizer.
Inventiva appoints Renée Aguiar-Lucander to its Board. As former CEO of Calliditas, she led its $1.1B sale to Asahi Kasei and FDA approval of TARPEYO®.
Adial advances Phase 3 design of AD04 for Alcohol Use Disorder with help from Cytel; trial to target genetic subgroups and launch in late 2025.
AbbVie’s MAVYRET® gets FDA approval to treat acute HCV in patients 3+, becoming the first 8-week regimen with 96% cure rate and Breakthrough Therapy status.
Biogen highlights felzartamab’s Phase 3 progress in AMR, IgAN, and PMN, targeting CD38+ cells for precise treatment of autoimmune and kidney diseases.
Vivani Medical names Anthony Baldor as CFO, succeeding Brigid Makes, to drive growth and advance its long-acting drug implant programs.
Capricor clears key FDA inspection, progressing Deramiocel toward potential approval for Duchenne muscular dystrophy under priority review.
Vanessa Tolosa and Vivek Pinto join Precision Neuroscience to drive innovation and clinical strategy in the brain–computer interface technology.
Chemomab receives FDA alignment on CMC and toxicology plans, advancing nebokitug toward Phase 3 trials for primary sclerosing cholangitis.
AIM secures U.S. patent for manufacturing methods of dsRNA, including Ampligen, strengthening IP protection and advancing development through 2041.
BioNTech to acquire CureVac in a $1.25B all-stock deal, aiming to boost mRNA innovation for cancer and infectious diseases with expanded R&D power.
Starton opens enrollment for Phase 2a trial of STAR-LLD, a continuous low-dose lenalidomide therapy, aiming to improve outcomes in multiple myeloma.
Fabhalta® achieves Hb normalization, fatigue reduction, and no transfusions in PNH patients switching from anti-C5 therapies, with long-term safety confirmed.
Novo Nordisk to begin Phase 3 trials of subcutaneous and oral amycretin for weight management in early 2026 after positive Phase 2 results.
Merck initiates Phase 3 trial for V181, a single-dose quadrivalent dengue vaccine, enrolling first participants in Singapore.
Rakesh Kumar Sinha shares his leadership journey, vaccine manufacturing insights, and vision for pharma excellence at Biological E in this exclusive interview.
Kirti Ganorkar to succeed Dilip Shanghvi as Sun Pharma’s MD from Sept 2025. Shanghvi to continue as Executive Chairman, focusing on strategic growth.
BIOPLUS-INTERPHEX KOREA debuts Asia Bio Connect, a trilateral biotech forum linking Korea, China, and Japan for collaboration and global integration.
London Biotechnology Show 2025 kicks off June 18–19 at ExCeL, showcasing biotech breakthroughs, global experts, and 100+ exhibitors across the industry.
Roche advances prasinezumab to Phase III for early Parkinson’s, aiming for first disease-modifying therapy with promising long-term data.
Roche pauses ELEVIDYS dosing in non-ambulatory DMD patients after two fatal liver failure cases; ambulatory use remains unchanged.
Dupixent significantly outperformed Xolair in all CRSwNP and asthma endpoints in the Phase 4 EVEREST trial, showing superior efficacy and similar safety.
Syncromune appoints Kerri-Ann Millar as CFO to lead financial strategy and support clinical advancement of its SYNC-T immunotherapy for solid tumors.
Teva and Fosun Pharma join forces to develop TEV-56278, an anti-PD1-IL2 immunotherapy aiming to enhance cancer treatment with targeted immune activation.
Osmol secures EU patent for OSM-0205, a novel drug to prevent chemo-induced neuropathy and cognitive issues in cancer patients.
Hepion names Dr. Lbiati interim CEO to lead strategic growth and expand its diagnostic programs for celiac disease, HCC, and respiratory infections.